Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D

Pemvidutide (2.4 mg), an investigational GLP-1/glucagon dual receptor agonist, helped people with obesity achieve an average 15.6% weight loss after 48 weeks in the phase II MOMENTUM trial, developer Altimmune announced.

Meanwhile, Pfizer said it would not proceed with phase III trials of its twice-daily danuglipron pill for weight loss, after more than half of participants dropped out of a phase II trial due to adverse events; the company is still evaluating a once-daily formulation of the investigational GLP-1 agonist.

While dapagliflozin (Farxiga) decreased cardiovascular events and suppressed left ventricular remodeling, it didn’t reduce urinary albumin excretion in patients with heart failure and diabetes. (eClinicalMedicine)

Five top obesity advocacy organizations called on the FDA to include people with obesity in clinical trials prior to a new drug being approved. They also called for drug labels to be updated with more effective dosing for people with obesity.

Novo Nordisk sued some Florida pharmacies after testing compounded versions of the weight-loss drug semaglutide (Wegovy) and finding them impure. (Reuters)

A nonprofit group aims to win FDA approval of estrogen for gender-affirming care. (STAT)

Oral vitamin D3 supplementation didn’t bolster bone strength or prevent bone fractures in Mongolian children ages 6 to 13 with vitamin D deficiency, according to a secondary analysis of a randomized trial. (The Lancet Diabetes & Endocrinology)

A longer reproductive period was tied to a decreased risk of low handgrip strength in postmenopausal women, a cross-sectional study in Korea showed. (Menopause)

Nonhormonal fezolinetant (Veozah) significantly reduced the frequency and severity of moderate to severe vasomotor symptoms at week 24 versus placebo in the phase IIIb DAYLIGHT study.

Analysis of corporate financial records showed that Novo Nordisk paid doctors — primarily obesity specialists — $25.8 million over 10 years to promote the company’s weight-loss drugs liraglutide (Saxenda) and semaglutide (Wegovy). (Reuters)

The FDA approved a generic version of the osteoporosis treatment teriparatide injection (Forteo), Ambio announced.

Real-world data found that people with obesity taking semaglutide or tirzepatide (Mounjaro) reduced their alcohol consumption. (Scientific Reports)

Walking more briskly may lower type 2 diabetes risk, a meta-analysis suggested. (British Journal of Sports Medicine)

Please enable JavaScript to view the

comments powered by Disqus.